101 related articles for article (PubMed ID: 8152278)
1. Adoptive immunotherapy with activated peripheral blood lymphocytes.
Horvath J; Sinkovics JG
Leukemia; 1994 Apr; 8 Suppl 1():S121-6. PubMed ID: 8152278
[TBL] [Abstract][Full Text] [Related]
2. Autologous activated lymphocyte therapy in a community hospital.
Horváth J; Szabó-Szabari M; Sinkovics JG
Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
[TBL] [Abstract][Full Text] [Related]
3. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
4. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
[TBL] [Abstract][Full Text] [Related]
5. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment.
Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):253-64. PubMed ID: 2215514
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
7. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
[TBL] [Abstract][Full Text] [Related]
8. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
10. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
12. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
13. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
14. [Clinical therapeutic effect of adoptive immunotherapy using IL-2-cultured autologous lymphocytes].
Kan N; Okino T; Nakanishi M; Satou K; Mise K; Ohgaki K; Hori T; Kodama H; Tobe T
Hum Cell; 1988 Sep; 1(3):289-96. PubMed ID: 2979206
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
18. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
19. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
[TBL] [Abstract][Full Text] [Related]
20. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]